Content
and Copyright
i
Superseded
This Document Has Been Replaced By:
i
Retired
This Document Has Been Retired
i
Up-to-date Information
This is the latest update:
Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
-
Published Date:
Apr 2004
-
Source:Emerg Infect Dis. 10(4):581-586.
-
[PDF-131.59 KB]
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti-SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral pharmacologic classes: nucleoside analogs, interferons, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors. Complete inhibition of cytopathic effects of SARS-CoV in culture was observed for interferon subtypes, b-1b, a-n1, a-n3, and human leukocyte interferon a. These findings support clinical testing of approved interferons for the treatment of SARS.
-
Subject:
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
- File Type:
-
Supporting Files:
image/gif 
image/jpeg 
image/gif 
image/jpeg 
text/plain
text/plain
No Related Documents.
Email
CDC-INFO
